REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
10/04/2025
Back to search
Official data from USPTO
SMARTAG
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
50
Latest update
10/05/2025
Trademark type
Word
Nice classes
1, 5
Filing date
06/18/2013
Registration date
10/04/2016
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/05/2023
Last transaction
10/05/2025
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
10/20/2014
First use in commerce
10/20/2014
Drawing code
4
Owner type
03
Owner location
Somerset, NJ
Examiner
LEVINE,HOWARD B
Law office
M60
Current location
TMO LAW OFFICE 115
Holders and representatives
Holders
CATALENT PHARMA SOLUTIONS, INC.
Representatives
Vanessa A. Ignacio, LOWENSTEIN SANDLER LLP
Technical classification
Nice Classes
Class 1Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicalbiochemical and biological reagents in the nature of or used to create or improve antibody-drug conjugates or any protein conjugated to a drugpoly nucleotideanother proteinchemicalother functional entity used in industry and science; chemicals for use in bioconjugationreversible bioconjugationirreversible bioconjugationreversible cysteine protectionsurface modificationprodrug production for scientific use; biochemicalspolypeptidespolypeptides for in vivo applicationspolypeptides for in vitro applicationspolynucleic acidspolynucleic acids for in vivo applicationspolynucleic acids for in vitro applications for scientific use; biomoleculesproteinspeptidesantibodiesantibody fragmentsantibody mimetic proteinspolynucleic acids for scientific use; chemical products for diagnostic useconjugates of polypeptides with small molecule drugsimaging agentsflourocromes and radiolabels for medical research applications; biochemical preparationspolypeptidespolynucleic acidsantibodiesall for use in basic scientific research and developmentmedical research; diagnostic preparations for scientific or research use in connection with antibody drug conjugates; biochemical preparationspolypeptidespolynucleic acidsantibodiesall for use in diagnosis and treatment of cancer and diseases and disorders of the immune systemrespiratory systemcardiovascular systemdigestive systemendocrine systemlymphatic systemmuscular systemskeletal systemnervous systemurinary systemintegumentary system and reproductive system
Class 5
Pharmaceutical preparations for the prevention or treatment of human diseasesdiseases of the immune systemrespiratory systemcardiovascular systemdigestive systemendocrine systemlymphatic systemmuscular systemskeletal systemnervous systemurinary systemintegumentary system and reproductive system; chemicalbiological and biochemical preparations for medical and pharmaceutical purposesantibody-drug conjugates or any protein conjugated to a drugpoly nucleotideanother proteinchemicalother functional entity or such preparations used as linker or payload molecules therein used to treat cancer and diseases and disorders of the immune systemrespiratory systemcardiovascular systemdigestive systemendocrine systemlymphatic systemmuscular systemskeletal systemnervous systemurinary systemintegumentary system and reproductive system; pharmaceutical preparationspolypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune systemrespiratory systemcardiovascular systemdigestive systemendocrine systemlymphatic systemmuscular systemskeletal systemnervous systemurinary systemintegumentary system and reproductive system; biological preparationspolypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune systemrespiratory systemcardiovascular systemdigestive systemendocrine systemlymphatic systemmuscular systemskeletal systemnervous systemurinary systemintegumentary system and reproductive system; diagnostic preparations for medical purposes in connection with the diagnosis and treatment of cancer and diseases and disorders of the immune systemrespiratory systemcardiovascular systemdigestive systemendocrine systemlymphatic systemmuscular systemskeletal systemnervous systemurinary systemintegumentary system and reproductive system; antibody preparationsantibody or protein bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune systemrespiratory systemcardiovascular systemdigestive systemendocrine systemlymphatic systemmuscular systemskeletal systemnervous systemurinary systemintegumentary system and reproductive systemincluding antibody/protein-drug conjugatesantibody/protein-radiolabled conjugates and antibody/protein-imaging agent conjugates; chemical products for medical diagnostic usepolypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune systemrespiratory systemcardiovascular systemdigestive systemendocrine systemlymphatic systemmuscular systemskeletal systemnervous systemurinary systemintegumentary system and reproductive system; biochemical preparationspolypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune systemrespiratory systemcardiovascular systemdigestive systemendocrine systemlymphatic systemmuscular systemskeletal systemnervous systemurinary systemintegumentary system and reproductive system
Publications
History of USPTO decisions and trademark events.
50 publications found
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
12/25/2024
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
10/05/2023
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
10/05/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/05/2023
E815
TEAS SECTION 8 & 15 RECEIVED
04/04/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
10/04/2021
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
05/22/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
10/04/2016
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
08/31/2016
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
08/30/2016
SUPC
STATEMENT OF USE PROCESSING COMPLETE
08/09/2016
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/06/2016
IUAF
USE AMENDMENT FILED
07/13/2016
EISU
TEAS STATEMENT OF USE RECEIVED
07/13/2016
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/19/2016
EX1G
SOU EXTENSION 1 GRANTED
01/15/2016
EXT1
SOU EXTENSION 1 FILED
01/15/2016
EEXT
SOU TEAS EXTENSION RECEIVED
01/15/2016
PCGR
PETITION TO DIRECTOR GRANTED
09/02/2015
APET
ASSIGNED TO PETITION STAFF
08/31/2015
TPDR
TEAS PETITION TO DIRECTOR RECEIVED
08/04/2015
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/28/2015
CHPN
POST PUBLICATION AMENDMENT – NOT ENTERED
07/25/2015
APET
ASSIGNED TO PETITION STAFF
07/22/2015
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
07/16/2015
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
06/16/2015
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
12/23/2014
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/02/2014
PUBO
PUBLISHED FOR OPPOSITION
12/02/2014
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/12/2014
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
10/28/2014
ALIE
ASSIGNED TO LIE
10/28/2014
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/09/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/17/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/17/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/17/2014
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/02/2014
GNRT
NON-FINAL ACTION E-MAILED
04/02/2014
CNRT
NON-FINAL ACTION WRITTEN
04/02/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/11/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/10/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/10/2014
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/16/2013
GNRT
NON-FINAL ACTION E-MAILED
09/16/2013
CNRT
NON-FINAL ACTION WRITTEN
09/16/2013
DOCK
ASSIGNED TO EXAMINER
09/10/2013
MPMK
NOTICE OF PSEUDO MARK E-MAILED
06/28/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/27/2013
NWAP
NEW APPLICATION ENTERED
06/21/2013
Continuous trademark protection
Get notified about every new filing that threatens SMARTAG or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.